EICHORCondition: Diabetes Mellitus, Type 2 · Sponsor: Novo Nordisk A/S
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.
This description comes directly from the study's public registry record.
Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion criteria * Male or female (sex at birth). * Age 18-75 years (both inclusive) at the time of signing the informed consent. * Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening. * Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline). Exclusion criteria * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| First Valley Medical Group | Lancaster, California, United States | Recruiting |
| Torrance Clinical Research Institute, Inc. | Lomita, California, United States | Recruiting |
| Ark Clinical Research | Long Beach, California, United States | Recruiting |
| Pacific Clinical Studies | Los Alamitos, California, United States | Recruiting |
| Wetlin Research Associates, Inc. | San Diego, California, United States | Recruiting |
| Diablo Clinical Research, Inc. | Walnut Creek, California, United States | Recruiting |
| Encore Medical Research LLC | Hollywood, Florida, United States | Recruiting |
| Bioclinical Research Alliance | Miami, Florida, United States | Recruiting |
| South Broward Research LLC | Miramar, Florida, United States | Recruiting |
| West Orange Endocrinology | Ocoee, Florida, United States | Not Yet Recruiting |
| Encore Medical Research of Weston | Weston, Florida, United States | Recruiting |
| Elite Clinical Trials | Blackfoot, Idaho, United States | Recruiting |
+ 51 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07415954